Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
Authors Kabeel MM, El-Batarny AM, Tameesh MK, Abou El Enein MA
Published 7 March 2008 Volume 2008:2(1) Pages 159—166
Mamdouh M Kabeel1, Ashraf M El-Batarny2, Mohamed K Tameesh3, Moustafa A Abou El Enein1
1Tanta University, Egypt, currently affiliated to Magrabi Eye and Ear Hospital, KSA, Vitreoretinal Service; 2Tanta University, Egypt, currently affiliated to Magrabi Eye and Ear Hospital, Muscat, Oman, Vitreoretinal Service; 3Tanta University, Egypt, currently affiliated to Saad Specialist Hospital, KSA, Vitreoretinal Service
Purpose: To test the results for patients treated with combined photodynamic therapy (PDT) with vertiporfin (Visudyne, Novartis AG) and intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Patients and methods: This is a prospective study including 18 eyes with subfoveal or juxtafoveal CNV secondary to AMD. Patients were treated with intravitreal bevacizumab 2.5 mg in the morning then PDT with vertiporfin in the evening of the same day. All patients were followed up for 6 months. The main outcome measures were stabilization (no change) or improvement of best corrected visual acuity (BCVA) with no leakage in fluorescein angiography (FLA) and reduction of central retinal thickness, and retreatment rate.
Results: At the end of 6 months follow up, all cases had either stabilization or improved BCVA. Fifteen eyes (80%) showed improved BCVA. The overall mean improvement in BCVA (n = 18) was 2.17 lines. Fifteen eyes (80%) required single combined treatment. Only 3 eyes (20%) required retreatment with the same protocol. No systemic or ocular complications were reported.
Conclusion: Combined intravitreal bevacizumab and PDT as a treatment of CNV secondary to AMD either for predominantly classic or occult subtypes has a positive therapeutic effect with stabilization or improvement of final BCVA and also might reduce the need for retreatment compared with literature retreatment rates of either modality alone.
Summary: Eighteen patients receiving combined therapy with PDT and intravitreal bevacizumab for CNV secondary to AMD, showed not only significant visual improvement but also reduction in the frequency of retreatment when compared to the results of monotherapy with each modality.
Keywords: intravitreal bevacizumab, photodynamic therapy, vertiporfin, choroidal neovascularization, age-related macular degeneration
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]